广东广康生化科技股份有限公司 证券代码：300804 证券简称：广康生化 公告编号：2025-058 押情况如下： （二）股东股份累计质押情况 截至本公告披露日，公司控股股东、实际控制人及其一致行动人所持股份质 | 蔡丹群 | 2,582.00 | 34.89% | 400.00 | 200.00 | 7.75% | 2.70% | 200.00 | | 100% | 2,382.00 | 100% | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 蔡绍欣 | 1,568.00 | 21.19% | 0 | 0 | 0 | 0 | | 0 | 0 | 1,568.00 | 100% | 1 关于控股股东、实际控制人部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 广东广康生化科技股份有限公司（以下简称"公司"）近日收到公司控股股 东、实际控制人蔡丹群先生的通知，获悉其将所持有的部分公司股份办理了解除 质押业务，相关解除质押登记手续已办 ...

广东广康生化科技股份有限公司 关于控股股东、实际控制人部分股份质押的公告 证券代码：300804 证券简称：广康生化 公告编号：2025-057 押情况如下： | 蔡丹群 | 2,582.00 | 34.89% | 300.00 | 400.00 | 15.49% | 5.41% | 400.00 | 100% | 2,182.00 | 100% | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 蔡绍欣 | 1,568.00 | 21.19% | 0 | 0 | 0 | 0 | 0 | 0 | 1,568.00 | 100% | | 广东众兴投资 管理有限公司 | 500.00 | 6.76% | 0 | 0 | 0 | 0 | 0 | 0 | 500.00 | 100% | 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 广东广康生化科技股份有限公司（以下简称"公司"）近日收到公司控股股 东、实际控制人蔡丹群先生的通知，获悉其将所持有的部分公司股份办理了质押 业 ...

Group 1 - The company Guangkang Biochemical announced the establishment of a joint venture, Shaoguan Henong Crop Technology Co., Ltd., with a registered capital of 3 million RMB, where Guangkang Biochemical holds 85% ownership [2] - The joint venture's business scope includes research and development of biopesticide technology and wholesale of pesticides [2] - Guangkang Biochemical was founded in October 2003 with a registered capital of 74 million RMB, focusing on the research, production, and sales of pesticide raw materials, intermediates, and formulations [2] Group 2 - In terms of financial performance, the company's revenue for 2022, 2023, 2024, and the first three quarters of 2025 were 660 million RMB, 495 million RMB, 723 million RMB, and 550 million RMB, with year-on-year growth rates of 1.34%, -24.99%, 46.15%, and 13.53% respectively [3] - The net profit attributable to the parent company for the same periods were 96.17 million RMB, 30.07 million RMB, 34.68 million RMB, and 34.85 million RMB, with year-on-year growth rates of -2.06%, -68.73%, 15.33%, and 47.09% respectively [3] - The company's asset-liability ratios for the same periods were 35.05%, 29.79%, 33.33%, and 37.80% [3]

Core Points - Guangkang Biochemical announced the establishment of a joint venture company, Shaoguan Henong Crop Technology Co., Ltd., in collaboration with individual investors [2] - The registered capital of the joint venture is RMB 3 million, with Guangkang Biochemical contributing RMB 2.55 million, representing 85% of the total capital [2] - The joint venture has completed the business registration process and obtained a business license from the market supervision administration [2]

公告 广东广康生化科技股份有限公司 证券代码：300804 证券简称：广康生化 公告编号：2025-056 关于对外投资进展暨控股孙公司取得营业执照的 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、对外投资概述 广东广康生化科技股份有限公司（以下简称"公司"）于2025年10月23日召 开第四届董事会第三次会议，审议通过了《关于全资子公司与关联方共同投资暨 关联交易的议案》，同意公司全资子公司广州禾农生物科技有限公司（以下简称 "广州禾农"）与自然人王世银先生、吴光辉先生、车林先生共同投资设立韶关 禾农作物科技有限公司（以下简称"合资公司"）。 合资公司注册资本为人民币300万元，其中：广州禾农以货币方式出资255 万元，占合资公司注册资本的85%；王世银先生、吴光辉先生、车林先生各以货 币方式出资15万元，分别占合资公司注册资本的5%。详见公司于2025年10月24 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于全资子公司与关联方共同 投资暨关联交易的公告》（公告编号：2025-053）。 二、对外投资的进展 近日，合资公司已完成工商 ...

证券代码：300804 证券简称：广康生化 公告编号：2025-055 广东广康生化科技股份有限公司 关于控股股东、实际控制人部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 1 | | | 广东广康生化科技股份有限公司（以下简称"公司"）近日收到公司控股股 东、实际控制人蔡丹群先生的通知，获悉其将所持有的部分公司股份办理了质押 业务，相关质押登记手续已办理完毕，具体事项如下： 一、股东股份质押的基本情况 （一）本次股份质押基本情况 | 深圳市中 | 2025 | 年 | 至办理解除 | 个人 | 是（首发前限 | 小担非融 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 蔡丹群 | 是 | 100.00 | 3.87% | 1.35% | 否 | 11 | 月 | 4 | 质押登记手 | 资金 | 售股） | 资性担保 | 日 | 续之日止 | 需求 ...

Core Viewpoint - Guangkang Biochemical experienced a decline of 2.41% in stock price on October 30, with a trading volume of 42.54 million yuan, indicating potential market volatility and investor sentiment concerns [1] Financing Summary - On October 30, Guangkang Biochemical had a financing buy-in amount of 3.42 million yuan and a financing repayment of 3.43 million yuan, resulting in a net financing buy of -3,800 yuan [1] - As of October 30, the total financing and securities lending balance for Guangkang Biochemical was 75.25 million yuan, accounting for 7.12% of its circulating market value, which is above the 60th percentile level over the past year, indicating a relatively high financing balance [1] - The company had no securities lending transactions on October 30, with a securities lending balance of 0.00 yuan, placing it in the 90th percentile level over the past year, suggesting a high level of securities lending activity [1] Company Overview - Guangkang Biochemical, established on October 17, 2003, and listed on June 27, 2023, is located in Tianhe District, Guangzhou, Guangdong Province [2] - The company specializes in the research, production, and sales of pesticide active ingredients, intermediates, and formulations, and is a major supplier of SDHI, trichloromethylthio fungicides, biphenyl hydrazine acaricides, and pyrethroid insecticides in China [2] - The revenue composition of Guangkang Biochemical includes 82.42% from active ingredients, 17.31% from formulations, 0.15% from pesticide intermediates, and 0.12% from other sources [2] Financial Performance - For the period from January to September 2025, Guangkang Biochemical achieved a revenue of 550 million yuan, representing a year-on-year growth of 13.53% [2] - The net profit attributable to shareholders for the same period was 34.84 million yuan, reflecting a significant year-on-year increase of 47.10% [2] Dividend Information - Since its A-share listing, Guangkang Biochemical has distributed a total of 49.95 million yuan in dividends [3]

Core Viewpoint - The company, Guangdong Guangkang Biochemical Technology Co., Ltd., has released its third-quarter financial report, ensuring the accuracy and completeness of the information disclosed, with no significant omissions or misleading statements [1][2]. Financial Data Summary - The third-quarter financial report has not been audited [6]. - The company does not require retrospective adjustments or restatements of previous accounting data [3]. - There are no non-recurring profit and loss items applicable to the company [3]. Shareholder Information - The report includes details on the total number of common shareholders and the top ten shareholders' holdings [4]. - There are no changes in the top ten shareholders due to securities lending activities [5]. Management Assurance - The board of directors, audit committee, and senior management have guaranteed the authenticity and completeness of the quarterly report, accepting legal responsibility for any inaccuracies [2].

Core Insights - Guangkang Biochemical reported a revenue of 549,873,806.69 yuan for the first three quarters of 2025, representing a year-on-year growth of 13.53% [2] - The net profit attributable to shareholders of the listed company was 34,848,362.42 yuan, showing a significant year-on-year increase of 47.10% [2] Financial Performance - Revenue for the first three quarters of 2025 reached approximately 549.87 million yuan, up from the previous year [2] - Net profit for the same period was around 34.85 million yuan, indicating strong growth compared to the prior year [2]

Major Events - Former Chairman of Beiyin Wealth Management, Fang Yi, has joined Huaxia Bank as Chief Risk Officer, pending regulatory approval [4] - Xilai Materials' subsidiary plans to invest 2 billion yuan in a semiconductor core component project, expected to generate over 1.5 billion yuan in annual output after reaching production [5][6] - Huatai Securities' subsidiary Huatai Futures has appointed Zhao Changtao as the new chairman [7] - Chuanfa Longmang's subsidiary plans to invest 366 million yuan in a 100,000 tons/year lithium dihydrogen phosphate project [8] - Huagong Technology is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange [9] - Jiangsu Leili's actual controller has changed from Su Jianguo to both Su Jianguo and Su Da due to internal share transfers [10] - Electric Power Investment Energy has been unable to contact independent director Han Fang, but this does not affect the board's operation [11] - Qiaqia Food's subsidiary is establishing an investment company focused on the leisure food industry with a total investment of 4 billion yuan [12][13] - Steel Research High-tech plans to set up a wholly-owned subsidiary in Saudi Arabia with an investment of up to 138 million yuan [14] - Yangjie Technology has terminated the acquisition of 100% equity in Better Electronics due to differences in business types and management [15] Performance Reports - Youfa Group reported a 2320.53% increase in net profit for Q3, despite a 3.97% decline in revenue [16] - Zhuoyi Information's net profit increased by 2074.65% in Q3, with revenue growth of 2.52% [17] - North Navigation's Q3 net profit surged by 1681.27%, with a 52.12% increase in revenue [18] - Tianneng Heavy Industry's net profit grew by 1359.03% in Q3, driven by increased sales of tower tubes [19] - Te Yi Pharmaceutical's net profit rose by 985.18% in Q3, with significant growth in traditional Chinese medicine sales [20] - Hualgreen Bio's Q3 net profit increased by 619.37%, with a 35.24% rise in revenue [21] - Zhenlei Technology's net profit grew by 598.09% in Q3, supported by strong revenue growth [22] - Shengyi Electronics expects a net profit increase of 476% to 519% for the first three quarters of 2025 [23] - Glodon reported a 244.89% increase in Q3 net profit, despite a slight decline in revenue [24] - Yingli Co., Ltd. saw a 229.14% increase in Q3 net profit, with a 14.73% rise in revenue [25] - Guangkang Biochemical's Q3 net profit increased by 236.87%, despite a decline in revenue [26] - High-speed Electric's Q3 net profit rose by 242.35%, with a 44.51% increase in revenue [27] - Wide Special Materials reported a 213.65% increase in net profit for Q3, driven by improved gross margins [28] - Baofeng Energy's Q3 net profit increased by 162.34%, attributed to increased production capacity [29] - Sanfu Co., Ltd. reported a 162.25% increase in Q3 net profit, driven by improved profitability of potassium and silane products [30] - Wuku New Energy's Q3 net profit increased by 106.31%, despite a loss in the first three quarters [32] - Pioneering Technology's Q3 net profit grew by 94.01%, supported by a recovery in the household energy storage market [33] - Sanlife Guojian's net profit increased by 71.15% in Q3, driven by project collaboration and CDMO business growth [34] - BGI Genomics reported a loss of 120 million yuan in the first three quarters, despite revenue growth [35] - Rejing Bio reported a net loss of 10.9 million yuan in the first three quarters, impacted by industry policies [36] - Jiangshan Oupai reported a net loss of 51.58 million yuan in Q3, attributed to market downturns and increased competition [38] - Taiping Bird reported a net loss of 49.45 million yuan in Q3, due to declining revenue and increased inventory losses [39] - Zhongke Tongda reported a loss of 6.87 million yuan in the first three quarters, affected by project delays and market competition [40] - Wolong New Energy reported a loss of 579.7 thousand yuan in Q3, transitioning from profit to loss [41] Major Contracts - Jinggong Steel Structure signed a significant overseas project contract worth approximately 1.23 billion yuan [42][43] - New Beiyang's subsidiary won a 105 million yuan postal equipment outsourcing project [44] - Maipu Medical plans to sign product sales agency agreements with related parties, with estimated procurement amounts of 21.5 million yuan and 3.5 million yuan [45] Shareholding Changes - Yunlu Co., Ltd. shareholder Guo Keyun plans to reduce his stake by up to 3% [46] Financing - Xinda Securities has received approval from the CSRC to issue up to 10 billion yuan in technology innovation corporate bonds [47]